Phase Ib/II Study of Radionuclide 177Lutetium-PSMA-617 Therapy in Combination With Pembrolizumab for Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)
Latest Information Update: 25 Jan 2025
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PRINCE
Most Recent Events
- 10 Apr 2024 Results (n=32) assessing Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment presented at the 115th Annual Meeting of the American Association for Cancer Research
- 24 Oct 2023 Results (n=37) assessing the associations of PET imaging and circulating tumour cells features at baseline with department of prostate specific antigen (PSA) response, presented at the 48th European Society for Medical Oncology Congress.
- 13 Mar 2023 Status changed from active, no longer recruiting to completed.